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Contraception is an important issue and should be a matter of concern in every medi-
cal  visit of adolescent and young patients with chronic rheumatic diseases. This narrative
review discusses contraception methods in adolescents with juvenile systemic lupus ery-
thematosus (JSLE), antiphospholipid syndrome (APS), juvenile idiopathic arthritis (JIA) and
juvenile dermatomyositis (JDM). Barrier methods are safe and their use should be encour-
aged  for all adolescents with chronic rheumatic diseases. Combined oral contraceptives
(COC) are strictly prohibited for JSLE and APS patients with positive antiphospholipid anti-
bodies. Reversible long-acting contraception can be encouraged and offered routinely to the
JSLE adolescent patient and other rheumatic diseases. Progestin-only pills are safe in the
majority of rheumatic diseases, although the main concern related to its use by adolescents
is  poor adherence due to menstrual irregularity. Depot medroxyprogesterone acetate injec-
tions  every three months is a highly effective contraception strategy, although its long-term
use  is associated with decreased bone mineral density. COC or other combined hormonal
contraceptive may be options for JIA and JDM patients. Oral levonorgestrel should be con-
sidered as an emergency contraception method for all adolescents with chronic rheumaticPlease cite this article in press as: Lourenc¸o B, et al. Contraception for adolescents with chronic rheumatic diseases. Rev Bras Reumatol. 2016.
http://dx.doi.org/10.1016/j.rbre.2016.07.016
diseases, including patients with contraindication to COC.
© 2016 Published by Elsevier Editora Ltda. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Contracepc¸ão para  adolescentes  com  doenc¸as  reumáticas  crônicas
Palavras-chave:
Contracepc¸ão
Doenc¸a reumática crônica
Lúpus eritematoso sistêmico
Anticorpo antifosfolípide
Contracepc¸ão de emergência
r  e  s  u  m  o
A contracepc¸ão é uma questão importante e deve ser um motivo de preocupac¸ão em
toda  consulta médica de pacientes adolescentes e jovens com doenc¸as reumáticas crôni-
cas.  Esta revisão narrativa discute métodos contraceptivos em adolescentes com lúpus
eritematoso sistêmico (LES), síndrome antifosfolipídica (SAF), artrite idiopática juvenil (AIJ)
e  dermatomiosite juvenil (DMJ). Os métodos de barreira são seguros e todos os adolescentes
com doenc¸as reumáticas crônicas devem ser incentivados a usá-los. Os contraceptivos orais
combinados (COC) são estritamente proibidos para pacientes com LESJ e SAF com anti-
corpos antifosfolípides positivos. A contracepc¸ão reversível de ac¸ão prolongada pode ser
incentivada e oferecida rotineiramente a paciente adolescente com LES e outras doenc¸as
reumáticas. As pílulas que contêm somente progestina são seguras na maior parte das
doenc¸as  reumáticas, embora a principal preocupac¸ão relacionada com seu uso por ado-
lescentes seja a baixa adesão em decorrência da irregularidade menstrual. As injec¸ões de
acetato de medroxiprogesterona de depósito a cada três meses são uma  estratégia altamente
eﬁcaz de contracepc¸ão, embora o seu uso em longo prazo esteja associado à diminuic¸ão na
densidade mineral óssea. Contraceptivos orais combinados ou outros contraceptivos hor-
monais combinados podem ser opc¸ões para pacientes com AIJ e DMJ. O levonorgestrel oral
deve ser considerado como um método de contracepc¸ão de emergência para todas as ado-
lescentes com doenc¸as reumáticas crônicas, incluindo pacientes com contraindicac¸ão para
COC.
©  2016 Publicado por Elsevier Editora Ltda. Este e´ um artigo Open Access sob uma
c¸a  Clicen
Introduction
The prevalence of chronic diseases has been rising
worldwide.1 In fact, approximately 20% of American adoles-
cents (12–17 years) have one current chronic disease and 13%
have two or more  current chronic diseases nowadays.2
Adolescents diagnosed with chronic illnesses and disabil-
ities live longer now than in the past. Those individuals
experience the enthusiasm of puberty, rapid growth, phys-
iologic changes and are usually engaged in socialization
processes, as any other adolescent. That said, the manage-
ment of chronic diseases during this special period constitutes
a major challenge for the individual, his/her family and the
health-care team.
The ﬁrst sexual intercourse has being occurring at earlier
ages throughout the world.3,4 Adolescents who initiate sexual
activity early in life tend to have more  sexual partners and are
more  prone to unintended pregnancies, since this behavior
is generally associated with low frequency of contraceptive
use.4,5
Although rates of teenage pregnancy have declined sig-
niﬁcantly in most countries during the last decades, a large
number of pregnancies still occur in this age group. Around 16
million adolescent women (15–19 years old) give birth each
year, approximately 11% of all births worldwide.6 The 2014
World Health Statistics shows that the average global birth
rate between 15 and 19 year olds is 49 per 1000 girls.7Please cite this article in press as: Lourenc¸o B, et al. Contraception for ado
http://dx.doi.org/10.1016/j.rbre.2016.07.016
Adolescents appear to be at higher risk for adverse preg-
nancy outcomes, such as low-birth-weight babies and infant
deaths.6,8–10 A multicountry study that included 124,446 moth-
ers ≤24 years, revealed that the risk of adverse outcomeC BY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/).
remained increased in adolescent (≤19 years) compared to
young mothers after controlling for country, marital sta-
tus, education levels and parity.10 Undesired pregnancies
may end in abortions, which are usually unsafe in this age
group.
Pregnancy in adolescents with chronic medical conditions
has been rarely studied, although it is an important issue in
clinical practice. Sexual desire is present in youth, indepen-
dently the severity of a possible chronic illness.11 Pregnancy
can also be particularly risky in female adolescent with active
disease or under teratogenic medication, making contracep-
tion an important issue for these women.
Despite adolescent contraception has become an impor-
tant public health issue, most physicians are still not aware
of the necessity to provide the right information and support
pregnancy prevention.12 Effective contraception is particularly
important for adolescents with chronic diseases, since the
consequences of an unwanted and unwished pregnancy can
be devastating.
In adolescent with chronic autoimmune conditions, dis-
ease activity at the time of conception and the presence of
antiphospholipid antibodies (aPL) are responsible for most
complications. Disease ﬂares, pre-eclampsia, and thrombo-
sis constitute maternal complications in adolescent with
systemic lupus erythematosus (SLE), whereas fetal loss, pre-
mature birth and intrauterine growth restriction are the main
fetal complications. Teratogenic drugs, such as immunosup-
pressive agents, implies the use of contraceptives.13lescents with chronic rheumatic diseases. Rev Bras Reumatol. 2016.
A clear understanding of the best contraceptive meth-
ods available for adolescents with chronic conditions is
essential to prevent unplanned pregnancies. Therefore, ado-
lescent and young patients should be educated about their
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Table 1 – Ten basic principles for choosing an
appropriate contraceptive strategy for adolescents with
rheumatic chronic diseases.
1. Consider adolescent with rheumatic chronic
disease as an individual with sexual desires,
shaped by their condition and with sexual and
reproductive rights
2. Respect the bioethical principles of privacy in
care and conﬁdentiality of information
3. Adopt a strategy of “dual protection” to
prevention of pregnancy and sexually
transmitted infections with condom
4. Consider the practical effectiveness of each
contraceptive method and understand the
typical adolescent use (not the perfect use)
5. Consider the eligibility criteria of each method
for each clinical condition, consulting existing
guidelines (WHO or CDC)
6. Understanding the adverse effects of the
methods, drug interaction and its possible
interference in disease progression
7. Consider accessibility and availability of
contraceptive method in the health system and
the cost of method.
8. Assess the teenager’s attitude towards the
exercise of their sexuality, their questions and
myths
9. Encourage the presence and participation of the
partner and the existence of family and/or social
support network to the issue of contraception
10. Develop strategies to the teenage couple. Healthy
providers are encouraged to help the negotiation
of contraceptive use with both partnersr  e v b r a s r e u m a t o l
ights to conﬁdential reproductive health care, sexual func-
ion and contraceptive methods. Contraception should be
iscussed in each medical visit with adolescent and young
atients. A recent study showed that approximately 30–55%
f female patients in reproductive age with chronic inﬂam-
atory diseases reported that their concerns relating to family
lanning were not adequately addressed during their medical
ppointments.14
Cochrane Database study reviewed more  then 41 tri-
ls (including more  that 95,000 teens) and concluded that
he combination of education and contraception promo-
ion was highly successful in pregnancy prevention for
dolescents.15
The most recent Youth Risk Behavior Surveillance in USA
eported that 41% of high school students did not use a con-
om and 14% did not use any contraceptive methods during
he last sexual intercourse.16 Therefore, to take a daily pill may
e challenging and other survey reported that teens are more
han twice as likely to experience a pill failure as women aged
ore  than 30 years.17
After the contraceptive choice, it is mandatory to evalu-
te prospectively the possible adverse events and adherence
or this strategy. These are important issues and may
e highlighted, particularly in adolescents with chronic
iseases.
Eligibility Criteria for Contraceptive Use,18 currently in its
th edition (2015), is a document published by the World
ealth Organization (WHO) which includes scientiﬁc evidence
o guide decision making on the safety of the use of various
ontraceptives in women with over than 60 medical condi-
ions. In 2010, the Centers for Disease Control (CDC) also
ublished a document for use in the USA, included other med-
cal diseases not included in the WHO  recommendations as
ariatric surgery, solid organ transplant and other chronic dis-
ases, such as inﬂammatory bowel disease and rheumatoid
rthritis.19 Both documents covers the current family plan-
ing methods.17,18
The both guidelines classiﬁed contraceptive methods for
arious diseases in 1–4 categories: category 1 includes dis-
ases without risk to contraceptive use; category 2 includes
ome medical risk to contraceptive; category 3 risks usually
utweigh contraceptive beneﬁts and contraceptive methods
re contraindicated in category 4.18,19
The objective of this article is a review regarding contra-
eption for adolescents with chronic autoimmune diseases.
ethods
e  performed a narrative review and conducted a series
f literature searches in the database MEDLINE/PubMed
or English language articles focusing on contraception in
dolescents with rheumatic diseases. The search strat-
gy included a combination of medical subject headings
nd keywords. The search terms that we  used were “con-
raception”, “adolescent”, “combined oral contraceptive”,Please cite this article in press as: Lourenc¸o B, et al. Contraception for ado
http://dx.doi.org/10.1016/j.rbre.2016.07.016
pediatric autoimmune diseases”, “juvenile idiopathic arthri-
is” (JIA), “juvenile rheumatoid arthritis”, “juvenile systemic
upus erythematosus” (JSLE), “childhood-onset systemic lupus
rythematosus”, “antiphospholipid syndrome” (APS) andWHO, World Health Organization; CDC, Centers for Disease Control.
“juvenile dermatomyositis”. The search covered the period
between 1970 and 2015 and included clinical studies, system-
atic reviews and animal studies. All articles selected for this
manuscript were full-text or review papers.
Table 1 includes the principles for choosing an appropriate
contraceptive strategy for adolescents with rheumatic chronic
diseases.
Contraception  for  juvenile  systemic  lupus
erythematosus
JSLE is a chronic autoimmune disease that can involve any
system and may lead to signiﬁcant morbidity and mortality.
Approximately 15–20% of SLE have disease before 18 years of
age.20 Sexually active adolescents with lupus are at high risk
for pregnancy. In addition to psychosocial risks related to early
pregnancy in the life of a teenager, risks for women with SLE
include disease ﬂares, obstetric and fetal complications, and
adverse effects of medications on fetal development.14
A cohort of women with SLE reported a high risk for
unplanned pregnancy, including many  patients under terato-
genic medications, 59% reported no contraceptive counseling
within the past year and 53% used only barrier contraceptivelescents with chronic rheumatic diseases. Rev Bras Reumatol. 2016.
methods.21
The majority of papers on contraception in SLE and
other chronic diseases were performed in adults. To our
ARTICLE IN PRESSRBRE-317; No. of Pages 9
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knowledge, there is no study of contraceptive methods for
JSLE adolescents. This is a very important point to consider,
since JSLE adolescents have a more  severe disease course
than adult-onset SLE. Therefore, they are prone to develop
signiﬁcant damage due to the disease, comorbidities and
treatments.22–24
According to the WHO  and CDC guidelines,18,19 barrier
methods for male contraception can be safely used by patients
with SLE (category 1). The condom use should be reinforced for
all male patients, especially under biological and immunosup-
pressive agents. Nonetheless, these methods have high failure
rates when used as the single contraceptive method, espe-
cially in teenagers.15 Thus, it is mandatory to indicate a more
reliable method in conjunction with barrier methods to avoid
pregnancy.
Regarding hormonal therapies, one of the concerns about
combined oral contraceptives (COC) to SLE patients is that
estrogen seems to play a major role in lupus pathophysio-
logy. JSLE often occurs in post-pubertal adolescent, supporting
the notion that SLE can be induced by estrogen. Indeed, some
autoimmune effects of estrogens have been related in vitro,
such as enhanced T-cell resistance to apoptosis and increased
levels of autoreactive B cells.25,26
Despite the common use of COC, many  physicians are
reluctant to prescribe this contraceptive to female SLE due to
concerns that exogenous estrogens could provoke lupus ﬂare.
Another issue is that estrogen has been associated with either
venous or arterial thrombosis.27
The SELENA (Safety of Estrogens in Lupus Erythematosus-
National Assessment) trial studied 183 young adult female SLE
patients, aged 18 years old or more,  with inactive or stable
disease. Previous history of thrombosis, positivity for anticar-
diolipin antibodies or lupus anticoagulant and hypertension
were exclusion criteria. COC did not increase the incidence
of severe or mild/moderate ﬂares when compared to placebo.
This study reinforced safety of COC for a subgroup of female
SLE who  had mild, stable disease and without antiphospho-
lipid antibodies.28
Sanchez-Guerrero et al.29 studied 162 adult women with
SLE in three different groups to evaluate the inﬂuence of
contraceptive methods (COC, progestin-only pill or copper
intrauterine device). There were no differences between these
groups in disease activity. During the study four patients had
thrombotic events, two in the COCs group and two in the
progestin-only pill group.
Association between COC use and venous thrombosis had
been reported.30 WHO  and CDC guidelines suggest that COCs
in the presence of antiphospholipid antibodies are strictly pro-
hibitive for SLE patients (category 4). On the other hand for
other SLE patients, even those with severe thrombocytopenia
or immunosuppressive treatment, this method is classiﬁed as
category 2. It is important to note that for all categories of
SLE, classiﬁcations are based on the assumption that no other
risk factors for cardiovascular disease are present and these
classiﬁcations must be modiﬁed in the presence of such risk
factors.18,19 COC prescription is contraindicated for arterialPlease cite this article in press as: Lourenc¸o B, et al. Contraception for ado
http://dx.doi.org/10.1016/j.rbre.2016.07.016
hypertension (systolic >160 or diastolic >100 mmHg) (category
3).18,19
Mature adolescents with SLE with negative antiphospho-
lipid antibodies, who  are nonsmokers, with neither family 1 6;x  x x(x x):xxx–xxx
nor personal history of thrombosis and with the disease
controlled, without renal involvement, may be eligible for
COC. To minimize the risk of thrombotic events, a low-
estrogen formulation should be chosen.31,32 Nevertheless, the
majority of adolescents with lupus do not present all the pre-
vious characteristics, therefore they are not good candidates
for estrogen-containing contraception, and other alternatives
should be considered.31,32
Regarding progestin contraceptive, Mintz et al.33 reported
progestogen use in SLE patients, either intramuscular
norethisterone enanthate or oral levonorgestrel. These contra-
ceptives were considered tolerable methods, in spite of 30% of
the patients had experienced intermenstrual bleedings, which
led to medication withdrawal.33 In addition, Julkunen et al.
also observed high withdrawal rates (78%) of progestin-only
pill (POP) preparation in SLE patients due to poor gynecological
tolerance, seemingly vaginal bleeding.34
A large retrospective study with more  than 74,000 women
that received progestogen presented augmented risks of
thrombosis. However, the relative risk was much higher in
women who used progestogens due to another indication,
but not as a contraception methods.35 Research addressing
thrombotic risk of progestin-only methods in high risk popu-
lations are not available.
WHO  recommends that POP are safe in the majority of SLE
patients, even in the presence of severe thrombocytopenia or
immunosuppressive drugs (category 2). If a patient has posi-
tive antiphospholipid antibodies, the method is classiﬁed as
category 3.18 The main concern related to the use by adoles-
cents is poor adherence due to menstrual irregularity.
Depot medroxyprogesterone acetate (DMPA) injections,
every three months, is a highly effective contraception
method. However, it has been observed that long-term use
of DMPA  is associated with decreased bone mineral density
(BMD), although with no known association with fracture
risks. The decrease in BMD in healthy adolescents may not be
clinically signiﬁcant, nevertheless for a teenager with lupus,
who have an increased risk of osteopenia due to either disease
itself or chronic glucocorticoid use, it might be a concern.32
Supplementation of calcium and vitamin D is required for
adolescents under DMPA.36
More recently, an implantable device with etonogestrel
(subdermal implant), another progestin-only contraceptive
method, can be an option for female SLE. Menstrual irregu-
larities are described, although this implant does not appear
to have an effect on BMD. This method is classiﬁed in WHO
guideline with the same categories for DMPA.
Long-acting reversible contraception (LARC) includes
intrauterine devices (IUDs) and subdermal implant. Although
these methods are considered as one of the most effec-
tive reversible contraception strategies, traditionally are not
offered routinely to the adolescent population. This concept,
however, has been modiﬁed in recent years. Approximately
4.5% of American girls 15–19 years use some of these methods,
mostly the IUDs.37 Recently, the American College of Obstetri-
cians and Gynecologists, the American Academy of Pediatrics,lescents with chronic rheumatic diseases. Rev Bras Reumatol. 2016.
the Center for Disease Control (CDC) and the WHO  indicate
the potential impact of adopting these methods in controlling
unplanned pregnancies, stating their safety and the lack of
future repercussions on fertility of women.38
ARTICLE IN PRESSRBRE-317; No. of Pages 9
 . 2 0 1
e
t
d
u
m
c
r
r
i
l
a
p
c
w
c
I
u
r
t
f
(
r
a
c
C
A
e
o
d
e
A
t
w
w
a
t
I
w
h
g
a
1
t
N
t
p
h
b
gr  e v b r a s r e u m a t o l
In addition to the contraceptive beneﬁts, the use of LARC
nsure optimal rates of adherence, an important parame-
er to be considered, particularly in adolescents with chronic
iseases. Studies have demonstrated high rates of contin-
ation of use with these methods, surpassing 85% over 12
onths both in younger women and older.39 This method
ombined with the use of condoms are also relevant to reduce
isk of sexually transmitted diseases and HIV infection. Cur-
ent evidence is that IUDs are safe. The relative risk of pelvic
nﬂammatory disease is increased only in the ﬁrst 20 days fol-
owing the device insertion, equaling the baseline population
fter this period.40 The IUDs with progestin may decrease the
elvic inﬂammatory disease risk because the thickening of the
ervical mucus and endometrial thinning. Pelvic infections
ere not observed in adult SLE patients, neither hemorrhagic
omplications with this method.29,34
According to the WHO,  the beneﬁt of using copper IUD (Cu-
UD) and levonorgestrel-IUD (LNG-IUD) in women with SLE
nder immunosuppressive treatment usually outweighs the
isks (category 2), except for patients with severe thrombocy-
openia (category 3 for Cu-IUD and 2 for LND-IUD). LNG-IUD
or patients with antiphospholipid antibodies has a high risk
category 3).18
Therefore, physicians should be considering long-acting
eversible and highly-effective contraception, such implants
nd intrauterine devices, for appropriately selected adoles-
ents with SLE.
ontraception  for  antiphospholipid  syndrome
PS is an autoimmune disorder characterized by the pres-
nce of antiphospholipid antibodies and thrombosis. It may
ccur as an isolated clinical entity or in association with other
iseases, mainly SLE.
Lakasing and Khamashta41 found seven thrombotic
pisodes in 32 COC users (22%) in non-pregnant women with
PS without any additional risk factors. This is more  than
wice the risk of thrombosis in non-pregnant women with APS,
ithout any additional risk factors. These data suggest that
omen with APS should not use this form of contraception.
Some authors have observed an increased prevalence of
ntiphospholipid antibodies in healthy women during COC
herapy, predominantly at the expense of anti-2-glycoprotein
 IgG class.42
In a randomized study of Sanchez-Guerrero et al.,29 women
ho  used combined or progestin-only oral contraception
ad the same rate of thrombosis (2 of 54 patients in each
roup), and all 4 patients with thrombosis had low titers of
ntiphospholipid antibodies.29 Asherson et al. 43 described
0 patients with aPL developing vascular complications while
aking COCs.
APS is a well-characterized prothrombotic condition.
evertheless, physicians’ ability to predict the risk of
hromboembolic phenomena for an asymptomatic antibody-
ositive individual is still limited. The association betweenPlease cite this article in press as: Lourenc¸o B, et al. Contraception for ado
http://dx.doi.org/10.1016/j.rbre.2016.07.016
igh dose of estrogen and venous thromboembolism has
een known for decades and some studies show that estro-
ens and progestogens are thought to be important in the 6;x  x x(x x):xxx–xxx 5
pathogenesis of arterial thrombosis.27,31,32 Therefore, use of
COC exerts an additive effect on the risk of thrombosis in
these patients, many  of them might not be aware of their
genetic phenotype. The combination of antiphospholipid
antibody and genetic prothrombotic risk factors increases the
risk of thrombosis. Even though this increase in risk, routine
screening in patients without a personal or family history
of thrombosis before starting COC is not recommended.18 It
is reasonable to assume that the frequency of thrombosis in
women taking hormonal contraception is increased if there
is already a predisposition to thromboembolic disease, espe-
cially in women with underlying thrombophilias (congenital
or acquired) and additional risk factors.
Other risk factors for arterial events, like complicated
migraines, atherosclerosis or hyperlipidemia, might be
increased in SLE patients with antiphospholipid antibodies,
and could also increase risk of stroke or myocardial infarction.
As a result, substantial concern has been expressed regarding
the prescription of COC to such women. It seems reasonable
to avoid COC in all patients with positive antiphospholipid
antibodies.43–46
Recent systematic review and meta-analysis was con-
ducted to evaluate the risk of venous thromboembolic events
associated with the use of progestin-only contraception.
The summary measure for the adjusted relative risk of
a venous thromboembolic episode for users versus non-
users of a progestin-only contraceptive was, based on the
random effects model, 1.03 (95% CI 0.76–1.39). Subgroup anal-
ysis conﬁrmed there was no association between venous
thromboembolic risk and POP or a progestin intrauterine
device.46
The WHO  guideline considers the use of progestogen-only
pills for SLE, category 3 for patients with positive antiphos-
pholipid antibodies, similar to the CDC guideline.18,19
DMPA could be a therapeutic alternative to COC in ado-
lescents with antiphospholipid antibodies, since progestin
only contraceptives are associated with a lower, if not absent,
risk of venous thromboembolic disease.47 DMPA  may cause
reversible osteoporosis and the fertility could be delayed after
discontinuation. The WHO  guideline considers initiation or
continuation of DMPA for SLE, category 3 for patients with
positive antiphospholipid antibodies.18 Similarly, the CDC
guideline considers as a category 3 the start of DMPA  for SLE
with antiphospholipid antibodies (or unknown), as well as the
continuation of the method.19
Other authors also reported the safety of DMPA  for con-
traception in females with antiphospholipid antibodies.48 In
addition, women with APS under warfarin should have ovula-
tion suppressed with intramuscular DMPA  to decrease severe
hemorrhagic corpus luteum complicating anticoagulation.
Hemorrhagic site reaction was not observed with this contra-
ceptive using this route of administration.49
A notable decrease in menstrual blood ﬂow is seen
with medroxyprogesterone acetate and the levonorgestrel-
releasing intrauterine system IUDs which might be par-
ticularly beneﬁcial in patients receiving treatment withlescents with chronic rheumatic diseases. Rev Bras Reumatol. 2016.
warfarin.50
In summary, the use of COC should be contraindicated in
adolescents with APS, given the increased thrombotic risk.
ARTICLE IN PRESSRBRE-317; No. of Pages 9
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Compounds of progestins and IUDs should be used with cau-
tion, mainly in anticoagulated adolescents and with risk of
reduction BMD.
Contraception  for  other  chronic  rheumatic
diseases
To our knowledge, there was no study regarding safety and
efﬁcacy of contraception in juvenile idiopathic arthritis pop-
ulation. Britto et al.51 studied adolescent risky behaviors,
including sexual activities, in 178 patients with pediatric-
onset rheumatic diseases, 69% of them had JIA. Sixty percent
of the females were sexually active and 41% were using con-
doms as the only contraceptive method.
Moreover, a recent Australian study showed higher rates
of maternal morbidity, pre-eclampsia and postpartum hem-
orrhage in JIA patients.52 Therefore, it is of the utmost
importance to inform the need of contraceptive methods
to avoid unplanned pregnancies. Rheumatoid arthritis (RA)
was added as a new condition speciﬁc to the USA context
in the CDC adaptation of the medical eligibility criteria for
contraceptive use from WHO.19 According to this guideline,
the use of combined hormonal contraceptive for rheumatoid
arthritis (with or without immunosuppressive therapy) is
category 2. CDC recommends that POP is safe in RA patients
(category 1); DMPA  is considered category 2/3 in patients on
immunosupressive therapy. LARC (LNG-IUD and Cu-IUD) is
a good option for rheumatoid arthritis patients (category
1) without immunosuppressive treatment; is consideredPlease cite this article in press as: Lourenc¸o B, et al. Contraception for ado
http://dx.doi.org/10.1016/j.rbre.2016.07.016
category 2 for initiation and category 1 for continuation in
patients on immunosuppressive treatment.19 JIA was not
included in the WHO  guidelines. Patients with JIA, especially
under immunosuppressive treatment, may possibly use
Table 2 – Contraceptive method recommendations and levels o
Rheumatic disease First suggestion
Barrier method
(male or female
condom) plus
SLE with negative
antiphospholipid
antibodies (aPL)
Copper-bearing IUD (A)29,31 or
levonorgestrel-releasing IUD
(C)18,38
SLE with positive (or
unknown)
aPL/antiphospholipid
syndrome
Copper-bearing IUD (NS) or
Levonorgestrel-releasing IUD
(C)18
SLE with severe
thrombocytopenia
Levonorgestrel-releasing IUD
(C)18
Other diseases (juvenile
idiopathic arthritis,
juvenile
dermatomyositis)
Combined oral contraceptive or
other combined hormonal
contraceptive (NS)
IUD, intrauterine device; DMPA, depot medroxyprogesterone acetate; NS, 
B, well-designed, nonrandomized clinical trial and level; C, consensus/exp 1 6;x  x x(x x):xxx–xxx
contraceptive recommendations such rheumatoid arthritis.
However further studies regarding safety and efﬁcacy of
contraception in JIA patients will be necessary.
The risk of pregnancy loss and prematurity have been
reported in patients with inﬂammatory myopathies.53 How-
ever, to our knowledge, there was no study regarding safety
and efﬁcacy of contraception in juvenile dermatomyositis
population. The WHO  and CDC guidelines did not include con-
traception for dermatomyositis.
Emergency  contraception
Although the eligibility criteria for contraceptive methods
prescription from WHO18 and CDC19 discuss the use of com-
bination pills or others non-hormonal methods for some
clinical conditions, the emergency contraception (EC) was not
included in these recommendations.
EC with oral levonorgestrel is a well understood, ethically
and technically legitimate mechanism for emergency situa-
tions, where no other protection method was used. It has
no medical contraindications and therefore can be used in
adolescents with rheumatic chronic diseases, including those
with contraindication to COC.54,55
EC with oral levonorgestrel should be used after unpro-
tected sex. It is effective when started less than 120 h after
sexual activity.54 To improve compliance, the single-dose
levonorgestrel-only treatment is indicated.
Table 2 illustrates the contraceptive method recommenda-lescents with chronic rheumatic diseases. Rev Bras Reumatol. 2016.
tions and levels of evidence56 for adolescents with rheumatic
chronic diseases.
Table 3 shows contraceptive methods with absolute con-
traindication for adolescents with chronic rheumatic diseases.
f evidence for patients with chronic rheumatic diseases.
Second  suggestion
Barrier method (male or
female condom) plus
Commentary
Combined oral contraceptive or
progestogen-only pills for
stable, mild disease activity
(A)28,29,31 or DMPA (C)13
In “contraceptive
accidents” at risk of
pregnancy (failure to use)
we indicate emergency
contraception (NS)Progestogen-only pills (B)31,46
or DMPA48,49
Combined oral contraceptive
for stable, mild disease activity
(NS)
Long-acting reversible
contraceptive (includes IUD or
implant) (NS)
In  “contraceptive
accidents” at risk of
pregnancy (failure to use)
we indicate emergency
contraception (NS)
no studies; level A, randomized controlled trial/meta-analysis; level
ert opinion.56
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Table 3 – Contraceptive methods with absolute contraindication for adolescents with chronic rheumatic diseases.
Rheumatic disease Contraceptive method with
absolute contraindication
JSLE with positive (or unknown)
antiphospholipid
antibodies/antiphospholipid syndrome
Combined oral contraceptive
Combined contraceptive patch
Combined contraceptive vaginal ring
Combined injectable contraceptive
JSLE with severe thrombocytopenia
Depot  medroxyprogesterone acetate (DMPA)
Copper-bearing intrauterine device (initiation)
Levonorgestrel-releasing intrauterine device (initiation)
Juvenile idiopathic arthritis None
Juvenile dermatomyositis None
C
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t
u
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2
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7
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r
1
1
1
1
1JSLE, juvenile systemic lupus erythematosus.
onclusion
dolescence is a period to consolidate identity, developing
 positive body image,  to establish social relationships and
o achieve independence and sexual identity. Clinicians must
nderstand that having pediatric rheumatic illness, even with
isability, does not prevent their youth from being sexually
ctive, becoming pregnant, or contracting sexually transmit-
ed diseases. The prevention of teenage pregnancy is complex
nd dynamic and the population of young people with access
o a reliable source of information, advice and support are
etter prepared to exercise a healthy and responsible sex-
ality. Based in our experience and to best adherence in
oung patients, we recommend that the contraceptive choice
or rheumatologic chronic disease should be prescribed by
heir own rheumatologists and eventually with a gynecologist
upervision.
onﬂicts  of  interest
he authors declare no conﬂicts of interest.
cknowledgements
his study was supported by grants from Fundac¸ão de Amparo
 Pesquisa do Estado de São Paulo (FAPESP 2009/51897-5,
011/12471-2 and 2014/14806-0 to CAS), Conselho Nacional de
esenvolvimento Cientíﬁco e Tecnológico (CNPQ 302724/2011-
 to CAS), Federico Foundation (to CAS), and Núcleo de Apoio
 Pesquisa “Saúde da Crianc¸a  e do Adolescente” da USP (NAP-
riAd) to CAS.
 e  f  e  r  e  n  c  e  s
1. WHO. The adolescent with a chronic condition; 2007.
Available from: http://www.who.int/maternal childPlease cite this article in press as: Lourenc¸o B, et al. Contraception for ado
http://dx.doi.org/10.1016/j.rbre.2016.07.016
adolescent/documents/9789241595704/en/ [accessed
15.06.15].
2.  National Survey of Children’s Health. NSCH 2011/12. Data
query from the child and adolescent health measurement
1initiative, data resource center for child and adolescent
health website. Available from: http://childhealthdata.
org/browse/survey/results?q=2473&r=1&g=448 [accessed
07.06.15].
3.  Pires R, Araújo-Pedrosa A, Pereira J, Canavarro MC.  Preventing
adolescent pregnancy: biological, social, and political
inﬂuences on age at ﬁrst sexual intercourse. J Primary
Prevent. 2014;35:239–54.
4. Oliveira-Campos M, Giatti L, Malta D, Barreto SM. Contextual
factors associated with sexual behavior among Brazilian
adolescents. Ann Epidemiol. 2013;23:629–35.
5. Shaﬁi T, Stovel K, Holmes K. Association between condom use
at  sexual debut and subsequent sexual trajectories: a
longitudinal study using biomarkers. Am J Public Health.
2007;97:1090–5.
6. WHO.  WHO  guidelines on preventing early pregnancy and
poor reproductive outcomes among adolescents in
developing countries; 2011. Available from: http://whqlibdoc.
who.int/publications/2011/9789241502214 eng.pdf?ua=1
[accessed 10.06.15].
7. WHO.  Adolescent pregnancy. Fact Sheet 364. Available from:
http://www.who.int/mediacentre/factsheets/fs364/en/
[accessed 05.06.15].
8. Paranjothy S, Broughton H, Adappa R, Fone D. Teenage
pregnancy: who suffers? Arch Dis Child. 2009;94:239.
9. Malabarey OT, Balayla J, Klam SL, Shrim A, Abenhaim HA.
Pregnancies in young adolescent mothers: a
population-based study on 37 million births. J Pediatr Adolesc
Gynecol. 2012;25:98–102.
0. Ganchimeg T, Ota E, Morisaki N, Laopaiboon M, Lumbiganon
P, Zhang J, et al. Pregnancy and childbirth outcomes among
adolescent mothers: a World Health Organization
multicountry study. BJOG. 2014;121:40.
1. Greydanus DE, Pratt HD, Patel DR. Concepts of contraception
for adolescent and young adult women with chronic illness
and disability. Dis Mon. 2012;58:258–320.
2. Hartman LB, Monasterio E, Hwang LY. Adolescent
contraception: review and guidance for pediatric clinicians.
Curr Probl Pediatr Adolesc Health Care. 2012;42:221–63.
3. Silva CA, Hilario MO, Febronio MV, Oliveira SK, Almeida RG,
Fonseca AR, et al. Pregnancy outcome in juvenile systemic
lupus erythematosus: a Brazilian multicenter cohort study. J
Rheumatol. 2008;35:1414–8.
4. Chacravarty E, Clowse ME, Pushparajah DS, Mertens S,
Gordon C. Family planning and pregnancy issues for women
with systemic inﬂammatory diseases: patient and physicianlescents with chronic rheumatic diseases. Rev Bras Reumatol. 2016.
perspectives. BMJ Open. 2014;4:e004081.
5. Oringanje C, Meremikwu MM, Eco H, Seu E, Meremikwu A,
Ehiri JE. Interventions for preventing unintended pregnancies
ARTICLE IN PRESSRBRE-317; No. of Pages 9
 l . 2 0
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
3
3
3
3
3
3
3
3
3
4
4
4
4
4
4
4
4
4
4
58  r e v b r a s r e u m a t o
among adolescents. Cochrane Database Syst Rev.
2009;4:CD005215.
6. Kann L, Kinchen S, Shanklin SL, Flint KH, Kawkins J, Harris
WA,  et al., Center for Disease Control and Prevention. Youth
Risk Behavior Surveillance — United States, 2013. MMWR.
2014;63:1–168.
7. Kost K, Singh S, Vaughan B, Trussel J, Bankole A. Estimates of
contraceptive failure from the 2002 National Survey of Family
Growth. Contraception. 2008;77:10–21.
8. WHO.  Medical eligibility criteria for contraceptive use. 5th ed.
Geneva: WHO; 2015. Available from: http://www.who.int/
reproductivehealth/publications/family planning/Ex-Summ-
MEC-5/en/.
9. Centers for Disease Control and Prevention. Medical eligibility
criteria for contraceptive use, 2010. Adapted from the World
Health Organization medical eligibility criteria for
contraceptive use, 4th edition. MMWR. 2010;59:1–86.
0. Silva CA, Avcin T, Brunner HI. Taxonomy for systemic lupus
erythematosus with onset before adulthood. Arthritis Care
Res (Hoboken). 2012;64:1787–93.
1. Yazdany J, Trupin L, Kaiser R, Schmajuk G, Gillis JZ,
Chakravarty E, et al. Contraceptive counseling and use among
women with systemic lupus erythematosus: a gap in health
care quality? Arthritis Care Res. 2011;63:358–65.
2. Silva CA, Hilário MO, Febrônio MV, Oliveira SK, Terreri MT,
Sacchetti SB, et al. Risk factors for amenorrhea in juvenile
systemic lupus erythematosus (JSLE): a Brazilian multicentre
cohort study. Lupus. 2007;16:531–6.
3. Tucker LB, Uribe AG, Fernández M, Vilá LM, McGwin G, Apte
M,  et al. Adolescent onset of lupus results in more aggressive
disease and worse outcomes: results of a nested matched
case–control study within LUMINA, a multiethnic US cohort
(LUMINA LVII). Lupus. 2008;17:314–22.
4. Gormezano NW, Silva CA, Otsuzi CI, Barros DL, da Silva MA,
Sallum AM, et al. Higher prevalence and distinct features of
herpes zoster infection in children than adults with systemic
lupus erythematosus. Pediatr Infect Dis J. 2015;34:905–7.
5. Petri M. Sex hormones and systemic lupus erythematosus.
Lupus. 2008;17:412–5.
6. Grimaldi CM. Sex and systemic lupus erythematosus: the role
of  the sex hormones estrogen and prolactin on the regulation
of  autoreactive B cells. Curr Opin Rheumatol. 2006;18:
456–61.
7. Stegeman BH, de Bastos M, Rosendaal FR, van Hylckama Vlieg
A, Helmerhorst FM, Stijnen T, et al. Different combined oral
contraceptives and the risk of venous thrombosis: systematic
review and network meta-analysis. BMJ. 2013;347:5298.
8. Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH,
Sammaritano LR, et al. Combined oral contraceptives in
women with systemic lupus erythematosus. N Engl J Med.
2005;353:2550–8.
9. Sanchez-Guerrero J, Uribe AG, Jiménez-Santana L,
Mestanza-Peralta M, Lara-Reyes P, Seuc AH, et al. A trial of
contraceptive methods in women with systemic lupus
erythematosus. N Engl J Med. 2005;353:2539–49.
0. World Health Organization Collaborative Study of
Cardiovascular Disease and Steroid Hormonal Contraception.
Venous thromboembolic disease and combined oral
contraceptives: results of international multicenter
case–control study. Lancet. 1995;346:1575–82.
1. Culwell KR, Curtis KM, del Carmen Cravioto M. Safety of
contraceptive method use among women with systemic
lupus erythematosus: a systematic review. Obstet Gynecol.
2009;114:341–53.
2. Tesher MS, Whitaker A, Gilliam M, Wagner-Weiner L, Onel KB.Please cite this article in press as: Lourenc¸o B, et al. Contraception for ado
http://dx.doi.org/10.1016/j.rbre.2016.07.016
Contraception for adolescents with lupus. Pediatr Rheumatol
Online J. 2010;8:10. 1 6;x  x x(x x):xxx–xxx
3. Mintz G, Gutiérrez G, Delezé M, Rodríguez E. Contraception
with progestogens in systemic lupus erythematosus.
Contraception. 1984;30:29–38.
4. Julkunen HA, Kaaja R, Friman C. Contraceptive practice in
women with systemic lupus erythematosus. Br J Rheumatol.
1993;32:227–30.
5. Vasilakis C, Jick H, Melero-Montes MM. Risk of idiopathic
venous thromboembolism in users of progestogens alone.
Lancet. 1999;354:1610–1.
6. Cromer BA, Scholes D, Berenson A, Cundy T, Clark MK,
Kaunitz AM, Society for Adolescent Medicine. Depot
medroxyprogesterone acetate and bone mineral density in
adolescents – The Black Box warning: a position paper of the
Society for Adolescent Medicine. J Adolesc Health.
2006;39:296–301.
7. Finer LB, Jerman J, Kavanaugh MC. Changes in use of
long-acting contraceptive methods in the United States,
2007–2009. Fertil Steril. 2012;98:893–7.
8. Mc Nicholas C, Peipert JF. Long-acting reversible contraception
for adolescents. Curr Opin Obstet Gynecol. 2012;24:293–8.
9. Peipert JF, Zhao Q, Allsworth JE, Petrosky E, Madden T,
Eisenberg D, et al. Continuation and satisfaction of reversible
contraception. Obstet Gynecol. 2011;117:1105–13.
0. Mohllajee AP, Curtis KM, Peterson HB. Does insertion and use
of an intrauterine device increase the risk of pelvic
inﬂammatory disease among women with sexually
transmitted infection? A systematic review. Contraception.
2006;73:145–53.
1. Lakasing L, Khamashta M. Contraceptive practices in women
with systemic lupus erythematosus and/or antiphospholipid
syndrome: what advice should we be giving? J Fam Plann
Reprod Health Care. 2001;27:7–12.
2. Vad S, Lakos G, Kiss E, Sipka S, Csorba R, Poka R.
Antiphospholipid antibodies in young women with and
without oral contraceptive use. Blood Coag Fibrinolys.
2003;14:57–60.
3. Asherson RA, Harris EN, Hughes GRV, Farquharson RG.
Complications of oral contraceptives and antiphospholipid
antibodies. Arthritis Rheum. 1988;31:575–6.
4. Choojitarom K, Verasertniyom O, Totemchokchyakarn K,
Nantiruj K, Sumethkul V, Janwityanujit S. Lupus nephritis and
Raynaud’s phenomenon are signiﬁcant risk factors for
vascular thrombosis in SLE patients with positive
antiphospholipid antibodies. Clin Rheumatol. 2008;27:
345–51.
5. Wahl DG, Guillemin F, de Maistre E, Perret C, Lecompte T,
Thibaut G. Risk for venous thrombosis related to
antiphospholipid antibodies in systemic lupus
erythematosus – a meta-analysis. Lupus. 1997;6:467–73.
6. Mantha S, Karp R, Raghavan V, Terrin N, Bauer A, Zwicker JI.
Assessing the risk of venous thromboembolic events in
women taking progestin-only contraception: a meta-analysis.
BMJ. 2012;345:e4944.
7. Tincani A, Nuzzo M, Lojacono A, Cattalini M, Meini A.
Contraception in adolescents with systemic lupus
erythematosus. Lupus. 2007;16:600–5.
8. Yamakami L, Seraﬁni P, de Araujo D, Bonfá E, Leon E, Baracat
E,  et al. Ovarian reserve in women with primary
antiphospholipid syndrome. Lupus. 2014;23:862–7.
9. Yamakami LY, de Araujo DB, Silva CA, Baracat EC, de Carvalho
JF. Severe hemorrhagic corpus luteum complicating
anticoagulation in antiphospholipid syndrome. Lupus.
2011;20:523–6.
0. Schaedel ZE, Dolan G, Powell MC. The use of the
levonorgestrel-releasing intrauterine system in thelescents with chronic rheumatic diseases. Rev Bras Reumatol. 2016.
management of menorrhagia in women with hemostatic
disorders. Am J Obstet Gynecol. 2005;193:1361–3.
ARTICLE IN PRESSRBRE-317; No. of Pages 9
 . 2 0 1
5
5
5
5
5
contraception. Am Fam Physician. 2010;82:1278.
56. Hadorn DC, Baker D, Hodges JS, Hicks N. Rating the quality ofr  e v b r a s r e u m a t o l
1. Britto MT, Rosenthal SL, Taylor J, Passo MH. Improving
rheumatologists’ screening for alcohol use and sexual
activity. Arch Pediatr Adolesc Med. 2000;154:478–83.
2. Chen JS, Ford JB, Roberts CL, Simpson JM, March LM.
Pregnancy outcomes in women with juvenile idiopathic
arthritis: a population-based study. Rheumatology (Oxford).Please cite this article in press as: Lourenc¸o B, et al. Contraception for ado
http://dx.doi.org/10.1016/j.rbre.2016.07.016
2013;52:1119–25.
3. Vancsa A, Ponyi A, Constantin T, Zeher M, Dankó K.
Pregnancy outcome in idiopathic inﬂammatory myopathy.
Rheumatol Int. 2007;27:435–9. 6;x  x x(x x):xxx–xxx 9
4. American Academy of Pediatrics Committee on Adolescence.
Emergency contraception. Pediatrics. 2012;130:
1174–82.
5. Armstrong C. ACOG recommendations on emergencylescents with chronic rheumatic diseases. Rev Bras Reumatol. 2016.
evidence for clinical practice guidelines. J Clin Epidemiol.
1996;49:749–54.
